Edick Paul R
SEC-identified person · CIK 1531178 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Vistagen Therapeutics, Inc. na | Director | filed 2025 - 2025 |
| Xeris Biopharma Holdings, Inc. XERS | Director · See Remarks | filed 2021 - 2024 |
| Xeris Pharmaceuticals INC XERS | Director · See Remarks | filed 2018 - 2021 |
| Milestone Pharmaceuticals Inc. MIST | Director | filed 2019 - 2020 |
| Iterum Therapeutics plc ITRM | Director | filed 2018 - 2019 |
| Protein Design Labs INC/DE pdli | Director | filed 2015 - 2018 |
| Sucampo Pharmaceuticals, Inc. SCMP | Director | filed 2016 - 2018 |
| Neos Therapeutics, Inc. NEOS | Director | filed 2015 - 2017 |
| Newlink Genetics Corp [NLNK] | Director | filed 2011 - 2017 |
| Durata Therapeutics, Inc. DRTX | Director · Chief Executive Officer | filed 2012 - 2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.